UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000007413
Receipt number R000008734
Scientific Title Phase II Study of Safety and Efficacy. Dasatinib in Patients with Chronic Phase Chronic Myelogenous Leukemia achieving a Major Molecular Response on Imatinib.
Date of disclosure of the study information 2012/03/01
Last modified on 2020/09/07 11:16:01

No. Disposal Last modified on Item of update
1 Insert 2012/03/01 10:00:28
2 Update 2012/03/01 10:14:40 Key exclusion criteria
3 Update 2012/03/02 15:27:20 Institutions
4 Update 2012/05/29 11:44:02 Recruitment status
5 Update 2012/10/01 09:35:15 Email
Email1
Institutions
6 Update 2012/10/17 14:14:10 Email
Email1
7 Update 2013/03/01 09:19:54 Institutions
8 Update 2013/09/01 09:08:25 Email
Email
Institutions
9 Update 2015/03/30 17:19:23 Recruitment status
10 Update 2016/12/14 16:06:44 Key inclusion criteria
11 Update 2016/12/14 16:07:32 Name of primary person or sponsor
Organization
12 Update 2020/09/07 11:08:44 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Address
Email1
Organization
Organization
Address
Address
Tel
Email
13 Update 2020/09/07 11:10:44 Number of participants that the trial has enrolled
14 Update 2020/09/07 11:13:31 Recruitment status
Date of IRB
Last follow-up date
15 Update 2020/09/07 11:15:34 Recruitment status
16 Update 2020/09/07 11:16:01 Recruitment status